Clinical trials indicate that RANKL inhibitor, denosumab, did not alter RA disease activity [27,85], and did not suppress joint space narrowing, although it caused sustained suppression of bone turnover in RA patients [27]. Here, TNFSF11 is linked to rheumatoid arthritis.